C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated